Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The data indicates encouraging response rates and robust CAR T-cell expansion with a manageable safety profile observed among the patients treated. The company plans to present updated findings during an oral presentation at the ASCO conference, further showcasing the potential of azer-cel in clinical development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Prospectus
- $20M placement and SPP, convertible notes amended
- 100% and 80% ORRs in Subset Indications in azer-cel study
- Trading Halt
Later from Imugene
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Complete Response in Concurrent BTKi azer-cel Cohort
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- $11.1 Million Placement Completed to Advance azer-cel
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene